In the rapidly evolving field of skin cancer medicine, it is important for GPs to be up to date with the latest developments to ensure patients receive the best possible care.

GPs are invited to join us for an evening with the experts in melanoma and complex non-melanoma skin cancer as they translate our latest understanding of the disease into the clinic setting.

Program:

Early detection: Essential knowledge for GPs - Dr Annika Smith (Dermatologist)
Surgical management of melanoma - A/Prof Alex van Akkooi (Surgeon)
Surgical management of non-melanoma skin cancer - A/Prof Sydney Ch’ng (Surgeon)
New developments in systemic treatment for early melanoma - A/Prof Alex Menzies (Medical Oncologist)

The evening will conclude with a multidisciplinary case study panel discussion and Q&A. (Program is subject to change)

You have the option to join us live at The Poche Centre in Sydney for networking and light refreshments, or from the comfort of your home via a live stream link.

Note: Although the presentations will commence at 6:30pm sharp, face-to-face ticket holders are invited to join us from 6pm for light refreshments and drinks at The Poche Centre. As The Poche Centre is a medical facility, in-person attendees must be fully vaccinated against Covid-19.

Cost: Free

CPD: This education is a CPD Activity under the RACGP CPD Program (Activity ID 329495) and ACRRM (Activity ID 25930).

Learning outcomes:

Identify high-risk melanoma patients and differentiate suspicious lesions using dermoscopy.
Recognise typical presentations of non-melanoma skin cancers and identify when adverse features indicate the need for specialist referral.
Discuss the importance of sentinel node biopsy as a prognostic tool to help risk stratify melanoma patients for adjuvant therapy and identify when a patient should be considered for this procedure.
Explain how adjuvant systemic drug therapy plays a role in the management of early melanoma and identify associated side effects.

MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb, Novartis and HEINE.